Gri Bio, INC. (GRI) — 10-Q Filings

10-Q Filings (6)

• GRI Bio's Losses Widen Amid Soaring R&D, Cash Dwindles — Nov 14, 2025 Risk: high
  GRI Bio, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $9,297 thousand, compared to $6,259 thousand fo
• GRI Bio's Losses Widen Amid Increased R&D, Going Concern Doubts Persist — Aug 14, 2025 Risk: high
  GRI Bio, Inc. reported a net loss of $2.892 million for the three months ended June 30, 2025, an increase from $2.250 million for the same period in 2024. For t
• GRI Bio, Inc. Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  GRI Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Vallon Pharmaceuticals, Inc., is focused on pharmaceutical pre
• GRI Bio, Inc. Files Q3 2024 10-Q — Nov 14, 2024 Risk: high
  GRI Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss for the nine months ended September 30, 2024, and its cas
• GRI BIO, Inc. Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  GRI BIO, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Vallon Pharmaceuticals, Inc., reported financial results for the second
• GRI BIO, Inc. Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: low
  GRI BIO, Inc. (GRI) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. GRI BIO, Inc. filed a 10-Q report for the period ending March 31, 2024. The co

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX